NOV 21, 2018
Comprehensive Ophthalmology, Pediatric Ophth/Strabismus
In this interview from AAO 2018, Dr. Donald Tan describes atropine therapy for treating children with myopia. Beginning in 1999, Dr. Tan and his team embarked on the ATOM 1 and ATOM 2 studies to determine the optimal concentration of atropine. Almost by accident, they discovered that 0.01% atropine could reduce the progression of myopia by 50 to 60% with minimal side effects. Now, his team is focused on preventing myopia with the launch ATOM 3 in Singapore. In this study, atropine treatment is initiated in younger children who are not yet myopic. Dr. Tan hopes that early atropine therapy will delay or prevent onset of myopia, and ultimately help reduce the prevalence of progression to high myopia.
Relevant Financial Disclosures: None